UCB selected Gwinnett County, Georgia for a new 460,000-square-foot biologics manufacturing facility expected to cost around $2 billion. The site is designed to use a digital-first approach leveraging AI, robotics and automation, with a target to produce complex biologics 24/7 primarily for the U.S. market. UCB described the Georgia facility as a supply-resilience move within its global biologics network. The company also framed the investment around reinforcing manufacturing capability ahead of pipeline demand and strengthening regional employment and infrastructure in the Atlanta metro life sciences ecosystem.